Abstract:Background: Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and PARP inhibitors. Standard diagnostic tests, including FDA-approved companion diagnostics, for detecting HRD require molecular profiling, which is not universally available with global testing rates lowest among minority, rural, and other underserved populations. Methods: We trained DeepHRD, a deep-learning platform for predicting HRD from hematoxylin and eosin (H&E)-stained histopathological slides, using primary breast (n=1,008) and ovarian (n=459) cancers from The Cancer Genome Atlas (TCGA). DeepHRD was compared to four standard HRD molecular tests using breast (n=349) and ovarian (n=141) cancers from multiple external and independent datasets, including clinical cohorts with platinum complete response, progression-free survival (PFS) and overall survival (OS) endpoints. Results: DeepHRD detected HRD from held-out H&E-stained breast cancer slides in TCGA with an AUC of 0.81 ([0.77-0.85]; 95% confidence interval). This performance was confirmed in two independent primary breast cancer cohorts (AUC=0.76; [0.71-0.82]). In an external platinum-treated metastatic breast cancer cohort, samples detected as HRD had a higher complete response (AUC=0.76; [0.54-0.93]) with 3.7-fold increase in median PFS (14.4 versus 3.9 months; p-value=0.0019) and hazard ratio (HR) of 0.45 (p=0.0047) after correcting for PAM50 molecular subtype and age at diagnosis. This deep-learning classifier outperformed four genomic HRD tests used in the clinic, including standard HRD score, BRCA1/2, 26-HR gene panel and single-base substitution signature 3 (SBS3). Multiresolution spatial mapping identified morphological features utilized by DeepHRD for detecting HRD, notably enriched for neoplastic and necrotic tissues, and a higher macrophage density. Through transfer learning to high-grade serous-ovarian cancer, DeepHRD-positive samples exhibited better overall survival after TCGA first-line (HR=0.46; p=0.030) and an external neoadjuvant (HR=0.49; p=0.015) platinum-treated cohorts. Conclusion: In summary, DeepHRD exhibits consistent hazard ratios ranging from 0.45 to 0.49 across the three clinical cohorts and captures 1.8- to 3.1-fold more HRD-positive breast and ovarian cancer patients. DeepHRD-positive breast cancer patients that received platinum exhibited better complete response and PFS. Similarly, DeepHRD-positive platinum-treated ovarian cancer patients had a better OS. DeepHRD's ability to detect HRD from digital H&E slides provides an important precision oncology tool that can be utilized in resource-constrained and underserved areas where genomic testing is generally not existent. Citation Format: Erik N. Bergstrom, Ammal Abbasi, Marcos Diaz-Gay, Loïck Galland, Sylvain Ladoire, Scott M. Lippman, Ludmil B. Alexandrov. Deep learning AI predicts HRD and platinum response from histologic slides [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB391.

Is Histopathology Deep Learning Artificial Intelligence the Future of Precision Oncology?

A Deep Learning Diagnostic Platform for Diffuse Large B-cell Lymphoma with High Accuracy Across Multiple Hospitals

Abstract LB391: Deep learning AI predicts HRD and platinum response from histologic slides

Deep learning in cancer genomics and histopathology

Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides

Deep learning in histopathology: the path to the clinic

Artificial intelligence in digital histopathology for predicting patient prognosis and treatment efficacy in breast cancer

Deep learning as a tool for increased accuracy and efficiency of histopathological diagnosis

Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images

Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology

A systematic pan-cancer study on deep learning-based prediction of multi-omic biomarkers from routine pathology images

Deep learning in cancer pathology: a new generation of clinical biomarkers

Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response

A systematic analysis of deep learning in genomics and histopathology for precision oncology

Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer

Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types

Machine learning enabled prediction of digital biomarkers from whole slide histopathology images

Scalable deep learning artificial intelligence histopathology slide analysis and validation

Abstract PO4-01-10: Multi-modal artificial intelligence models from baseline histopathology predict prognosis in HR+ HER2- early breast cancer

Computational pathology in cancer diagnosis, prognosis, and prediction – present day and prospects

Emerging Role of Deep Learning‐based Artificial Intelligence in Tumor Pathology